BRIDGEBIO PHARMA INC (BBIO)
US10806X1028 - Common Stock
BRIDGEBIO PHARMA INC
NASDAQ:BBIO (1/3/2025, 8:21:43 PM)
After market: 28.14 +0.02 (+0.07%)28.12
-0.08 (-0.28%)
Company Profile
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 550 full-time employees. The company went IPO on 2019-06-27. The firm is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The firm's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.
Company Info
BRIDGEBIO PHARMA INC
3160 Porter Dr., Suite 250
Palo Alto CALIFORNIA 94301
P: 16503919740
CEO: Neil Kumar
Employees: 553
Website: https://bridgebio.com/
BBIO News
22 days ago - BridgeBio Pharma, Inc.Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)22 days ago - BridgeBio Pharma, Inc.Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on positive results from the Phase 3...
a month ago - Market News VideoNoteworthy Monday Option Activity: KODK, TGT, BBIOa month ago - Investor's Business DailyBridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart DrugBridgeBio will sell its drug at a slightly lower wholesale acquisition cost compared to Pfizer's blockbuster, Vyndaqel.
a month ago - BridgeBio Pharma, Inc.Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patientsa month ago - BridgeBio Pharma, Inc.Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native...
BBIO Twits
Here you can normally see the latest stock twits on BBIO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
